Inhibrx is heading to #ESMO2026, where data from the primary analysis of the phase 2 HexAgon-HN study evaluating ordastobart (INBRX-106) will be presented. 📅 Oct. 25

Inhibrx Biosciences, Inc.· @inhibrx · X·2026-10-23 04:12· 17 hours agoScore60

Body

Inhibrx is heading to #ESMO2026, where data from the primary analysis of the phase 2 HexAgon-HN study evaluating ordastobart (INBRX-106) will be presented. 📅 Oct. 25 | 8:30–8:30–8:40 AM CET 📍 Booth #1077, Hall 10 Session details: https://t.co/cGgQNmYPRc https://t.co/09gpprjbaB

Heat 0 · 0 likes · 0 replies · 0 reposts

Source: Inhibrx Biosciences, Inc. · x.com